Drug Abuse Treatment Development and Research Mentoring

描述(由申请人提供)：这份K24职业生涯中期临床医生-科学家提案的目标是允许候选人Edward Nunes博士继续扩大他在药物滥用治疗开发领域的研究和研究指导计划。这位候选人的研究计划集中在两个相关的主题上，即治疗药物依赖患者的共生精神病理学，以及开发药物依赖的行为和药物治疗的组合。主要活动和成就包括一系列研究，考察抗抑郁药物治疗阿片类药物、可卡因和酒精依赖抑郁症患者的疗效，将行为疗法的进展应用于阿片类药物依赖的纳曲酮维持和美沙酮维持患者的抑郁治疗，应用行为疗法加强可卡因药物开发试验的设计，以及NIDA临床试验网络中的多点有效性试验。通过与同事的合作和工作，努内斯博士已经并继续指导他的议程扩大到研究结构化精神诊断方法、艾滋病毒风险降低以及其他共同发生的精神病理学，包括注意力缺陷多动障碍、冲动性攻击、创伤后应激障碍、病理性赌博、神经心理功能以及儿童精神病理学和药物依赖风险。在拟议的K24期间，Nunes博士将担任一个中心项目、两个R01项目和临床试验网络长岛节点的首席研究员，以及初级同事资助项目和导师K奖的联合L、发起人或共同发起人。特别是，K24将解放Nunes博士的时间，并提供资源，以寻求治疗研究中新倡议和新合作的发展，并为初级同事创造以患者为导向的研究机会。该指导计划将面向三个主要层面的年轻研究人员，1)拥有早期或新兴独立研究项目的初级教员，其中许多人是努内斯博士自奖学金以来或在K奖项期间指导的；2)努内斯博士作为赞助人的三名K23获奖者，以及他作为共同赞助人或顾问的三名K23或K01获奖者；以及3)NIDA资助的T32研究奖学金计划中临床研究的博士后研究员。此外，努内斯博士将寻求促进独立的研究倡议和合作，包括参与临床试验网络的社区治疗项目的临床领导。最终目标是通过临床研究改善药物依赖患者的治疗，并帮助培养下一代临床医生-研究人员。

DESCRIPTION (provided by applicant): The goal of this K24 Mid-Career Clinician-Scientist proposal is to allow the Candidate, Dr. Edward Nunes, to continue to expand his program of research and research mentorship in the field of drug abuse treatment development. The Candidate's research program focuses on two related themes, the treatment of co-occurring psychopathology in substance dependent patients, and the development of combinations of behavioral and pharmacological treatments for drug dependence. Major activities and accomplishments have included a series of studies examining the efficacy of antidepressant medications for treatment of opioid, cocaine, and alcohol dependent patients with depression, projects applying advances in behavioral therapies to naltrexone maintenance for opioid dependence and to treatment of depression among methadone maintained patients, applications of behavioral therapy to enhance the design of cocaine medications development trials, and multi-site effectiveness trials in the NIDA Clinical Trials Network. Through collaborations and the work of colleagues Dr. Nunes has, and continues to mentor, his agenda has expanded to examine structured psychiatric diagnostic methods, HIV risk reduction, and other co-occurring psychopathology including attention deficit hyperactivity disorder, impulsive aggression, post-traumatic stress disorder, pathological gambling, neuropsychological functioning, and childhood psychopathology and risk for drug dependence. Over the course of the proposed K24 Dr. Nunes will serve as Principle Investigator on a Center Project, two R01s, and the Long Island Node of the Clinical Trials Network, and as Co-l, Sponsor, or Co-Sponsor on funded projects of junior colleagues and mentored K awards. In particular the K24 will free Dr. Nunes' time and provide resources to pursue the development of new initiatives and collaborations in treatment research and to create opportunities in patient-oriented research for junior colleagues. The mentoring plan will serve young investigators at three main levels, 1) junior faculty with early or emerging independent research programs many of whom Dr. Nunes has mentored since fellowship or during K awards, 2) three current K23 awardees for whom Dr. Nunes serves as Sponsor, and three current (or anticipated) K23 or K01 awardees for whom he serves as Co-Sponsor or Consultant, and 3) Post doctoral fellows in clinical research in the Department's NIDA funded T32 research fellowship program. In addition Dr. Nunes will seek to foster independent research initiatives and collaborations involving the clinical leadership of community-based treatment programs participating in the Clinical Trials Network. The ultimate goals are to improve the treatment of drug dependent patients through clinical research and to help foster the next generation of clinician-researchers.